Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

Genesis Healthcare (GEN)

Genesis Healthcare Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NYSE:GEN
DateTimeSourceHeadlineSymbolCompany
24/01/202311:27GlobeNewswire Inc.Genmab Announces Net Sales of DARZALEX® (daratumumab) for 2022NYSE:GENGenesis Healthcare Inc
11/11/202201:49TipRanksRBC Capital Keeps Their Hold Rating on Gen Digital (GEN)NYSE:GENGenesis Healthcare Inc
09/11/202216:01GlobeNewswire Inc.Genmab Announces Financial Results for the First Nine Months of 2022NYSE:GENGenesis Healthcare Inc
03/11/202216:45GlobeNewswire Inc.Genmab Improves Its 2022 Financial GuidanceNYSE:GENGenesis Healthcare Inc
18/10/202211:35GlobeNewswire Inc.Genmab Announces Net Sales of DARZALEX® (daratumumab) for the Third Quarter of 2022NYSE:GENGenesis Healthcare Inc
05/10/202220:56GlobeNewswire Inc.Major Shareholder AnnouncementNYSE:GENGenesis Healthcare Inc
10/08/202216:01GlobeNewswire Inc.Genmab Announces Financial Results for the First Half of 2022NYSE:GENGenesis Healthcare Inc
08/08/202217:33GlobeNewswire Inc.Genmab Improves Its 2022 Financial GuidanceNYSE:GENGenesis Healthcare Inc
02/08/202219:46GlobeNewswire Inc.Major Shareholder AnnouncementNYSE:GENGenesis Healthcare Inc
20/07/202218:03GlobeNewswire Inc.Major Shareholder AnnouncementNYSE:GENGenesis Healthcare Inc
19/07/202211:33GlobeNewswire Inc.Genmab Announces Net Sales of DARZALEX® (daratumumab) for the Second Quarter of 2022NYSE:GENGenesis Healthcare Inc
18/07/202215:01GlobeNewswire Inc.Genmab Announces That AbbVie Will Submit Marketing Authorization Application to European Medicines Agency for Epcoritamab (DuoBody®-CD3xCD20) for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)NYSE:GENGenesis Healthcare Inc
11/07/202216:28GlobeNewswire Inc.Major Shareholder AnnouncementNYSE:GENGenesis Healthcare Inc
01/07/202215:14GlobeNewswire Inc.Major Shareholder AnnouncementNYSE:GENGenesis Healthcare Inc
30/06/202219:24GlobeNewswire Inc.Genmab to Submit Biologics License Application to U.S. Food and Drug Administration for Epcoritamab (DuoBody®-CD3xCD20) for the Treatment of Relapsed/Refractory Large B-Cell Lymphoma (LBCL)NYSE:GENGenesis Healthcare Inc
20/06/202215:35GlobeNewswire Inc.Major Shareholder AnnouncementNYSE:GENGenesis Healthcare Inc
09/06/202222:17GlobeNewswire Inc.Genmab Commences New Arbitration Under License Agreement With JanssenNYSE:GENGenesis Healthcare Inc
01/06/202217:21GlobeNewswire Inc.Major Shareholder AnnouncementNYSE:GENGenesis Healthcare Inc
11/05/202216:01GlobeNewswire Inc.Genmab Announces Financial Results for the First Quarter of 2022NYSE:GENGenesis Healthcare Inc
19/04/202211:29GlobeNewswire Inc.Genmab Announces Net Sales of DARZALEX® (daratumumab) for First Quarter of 2022NYSE:GENGenesis Healthcare Inc
13/04/202222:25GlobeNewswire Inc.Genmab and AbbVie Announce Topline Results for Epcoritamab (DuoBody®-CD3xCD20) From Phase 1/2 Trial in Patients with Relapsed/Refractory Large B-cell Lymphoma (LBCL)NYSE:GENGenesis Healthcare Inc
08/04/202200:44GlobeNewswire Inc.Genmab Announces the Initial Resolution of its Arbitration with Janssen Relating to their Daratumumab License AgreementNYSE:GENGenesis Healthcare Inc
24/02/202211:01GlobeNewswire Inc.Notice to Convene the Annual General Meeting of Genmab A/SNYSE:GENGenesis Healthcare Inc
16/02/202216:00GlobeNewswire Inc.Genmab Publishes 2021 Annual ReportNYSE:GENGenesis Healthcare Inc
25/01/202211:30GlobeNewswire Inc.Genmab Announces Net Sales of DARZALEX® (daratumumab) for 2021NYSE:GENGenesis Healthcare Inc
04/01/202214:00GlobeNewswire Inc.Genmab and Synaffix Enter into License Agreement for ADC TechnologyNYSE:GENGenesis Healthcare Inc
10/11/202116:00GlobeNewswire Inc.Genmab Announces Financial Results for the First Nine Months of 2021NYSE:GENGenesis Healthcare Inc
04/11/202120:24GlobeNewswire Inc.Genmab Improves its 2021 Financial GuidanceNYSE:GENGenesis Healthcare Inc
19/10/202111:29GlobeNewswire Inc.Genmab Announces Net Sales of DARZALEX® (daratumumab) for the Third Quarter of 2021NYSE:GENGenesis Healthcare Inc
21/09/202119:22GlobeNewswire Inc.Capital Increase in Genmab as a Result of Employee Warrant ExerciseNYSE:GENGenesis Healthcare Inc
 Showing the most relevant articles for your search:NYSE:GEN

Your Recent History

Delayed Upgrade Clock